FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3117475035> ?p ?o ?g. }

• W3117475035 abstract "Abstract Background Human leukocyte antigen class 1 (HLA-1)–dependent immune activity is linked to autoimmune diseases. HLA-1–dependent CD8+ T cells are required for immune checkpoint blockade antitumor activity. It is unknown if HLA-1 genotype is predictive of toxicity to immune checkpoint blockade. Methods Patients with advanced solid tumors stratified into 5 cohorts received single agent pembrolizumab (anti-programmed cell death-1) 200 mg intravenously every 3 weeks in an investigator-initiated phase II trial (Investigator-Initiated Phase II Study of Pembrolizumab Immunological Response Evaluation study, NCT02644369). Germline whole-exome sequencing of peripheral blood mononuclear cells was performed using the Illumina HiSeq2500 platform. HLA-1 haplotypes were predicted from whole-exome sequencing using HLAminer and HLAVBSeq. Heterozygosity of HLA-A, -B, and -C, individual HLA-1 alleles, and HLA haplotype dimorphism at positions −21 M and −21 T of the HLA-A and -B leader sequence were analyzed as predictors of toxicity defined as grade 2 or greater immune-related adverse events and clinical benefit defined as complete or partial response, or stable disease for 6 or more cycles of pembrolizumab. Statistical significance tests were 2-sided. Results In the overall cohort of 101 patients, the frequency of toxicity and clinical benefit from pembrolizumab was 22.8% and 25.7%, respectively. There was no association between any of the HLA-1 loci or alleles with toxicity. HLA-C heterozygosity had an association with decreased clinical benefit relative to HLA-C homozygosity when controlling for cohort (odds ratio = 0.28, 95% confidence interval = 0.09 to 0.91, P = .04). HLA-A and -B haplotype −21 M/T dimorphism and heterozygosity of HLA-A, -B, and -C were not predictive of outcomes. Conclusions HLA-C heterozygosity may predict decreased response to pembrolizumab. Prospective validation is required." @default.
• W3117475035 created "2021-01-05" @default.
• W3117475035 creator A5000204204 @default.
• W3117475035 creator A5006324055 @default.
• W3117475035 creator A5022267545 @default.
• W3117475035 creator A5031076350 @default.
• W3117475035 creator A5031467567 @default.
• W3117475035 creator A5037435508 @default.
• W3117475035 creator A5043806671 @default.
• W3117475035 creator A5051951094 @default.
• W3117475035 creator A5072207500 @default.
• W3117475035 creator A5074224747 @default.
• W3117475035 creator A5076090440 @default.
• W3117475035 creator A5076364548 @default.
• W3117475035 creator A5076699033 @default.
• W3117475035 creator A5088186975 @default.
• W3117475035 date "2020-12-29" @default.
• W3117475035 modified "2023-10-11" @default.
• W3117475035 title "Predicting Toxicity and Response to Pembrolizumab Through Germline Genomic HLA Class 1 Analysis" @default.
• W3117475035 cites W1482164699 @default.
• W3117475035 cites W1493511814 @default.
• W3117475035 cites W1501839163 @default.
• W3117475035 cites W1940241680 @default.
• W3117475035 cites W1970753581 @default.
• W3117475035 cites W2020469275 @default.
• W3117475035 cites W2042543697 @default.
• W3117475035 cites W2049553585 @default.
• W3117475035 cites W2057499380 @default.
• W3117475035 cites W2061262594 @default.
• W3117475035 cites W2066319119 @default.
• W3117475035 cites W2068116723 @default.
• W3117475035 cites W2079018735 @default.
• W3117475035 cites W2112121482 @default.
• W3117475035 cites W2125082756 @default.
• W3117475035 cites W2143350483 @default.
• W3117475035 cites W2152897456 @default.
• W3117475035 cites W2156353875 @default.
• W3117475035 cites W2164090407 @default.
• W3117475035 cites W2166662937 @default.
• W3117475035 cites W2184123611 @default.
• W3117475035 cites W2201214180 @default.
• W3117475035 cites W2214699570 @default.
• W3117475035 cites W2268018597 @default.
• W3117475035 cites W2289841322 @default.
• W3117475035 cites W2299181842 @default.
• W3117475035 cites W2301707196 @default.
• W3117475035 cites W2345568581 @default.
• W3117475035 cites W2370999228 @default.
• W3117475035 cites W2397739282 @default.
• W3117475035 cites W2462014591 @default.
• W3117475035 cites W2520496580 @default.
• W3117475035 cites W2525217971 @default.
• W3117475035 cites W2549481046 @default.
• W3117475035 cites W2559382297 @default.
• W3117475035 cites W2559953355 @default.
• W3117475035 cites W2560367415 @default.
• W3117475035 cites W2572174216 @default.
• W3117475035 cites W2587242369 @default.
• W3117475035 cites W2759963646 @default.
• W3117475035 cites W2761575992 @default.
• W3117475035 cites W2762253884 @default.
• W3117475035 cites W2766209631 @default.
• W3117475035 cites W2774712455 @default.
• W3117475035 cites W2786224778 @default.
• W3117475035 cites W2883970691 @default.
• W3117475035 cites W2892038061 @default.
• W3117475035 cites W2904276001 @default.
• W3117475035 cites W2904731239 @default.
• W3117475035 cites W2944392072 @default.
• W3117475035 cites W2963603102 @default.
• W3117475035 cites W2968188498 @default.
• W3117475035 cites W3061157080 @default.
• W3117475035 cites W94644913 @default.
• W3117475035 doi "https://doi.org/10.1093/jncics/pkaa115" @default.
• W3117475035 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7853183" @default.
• W3117475035 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33554038" @default.
• W3117475035 hasPublicationYear "2020" @default.
• W3117475035 type Work @default.
• W3117475035 sameAs 3117475035 @default.
• W3117475035 citedByCount "11" @default.
• W3117475035 countsByYear W31174750352020 @default.
• W3117475035 countsByYear W31174750352021 @default.
• W3117475035 countsByYear W31174750352022 @default.
• W3117475035 countsByYear W31174750352023 @default.
• W3117475035 crossrefType "journal-article" @default.
• W3117475035 hasAuthorship W3117475035A5000204204 @default.
• W3117475035 hasAuthorship W3117475035A5006324055 @default.
• W3117475035 hasAuthorship W3117475035A5022267545 @default.
• W3117475035 hasAuthorship W3117475035A5031076350 @default.
• W3117475035 hasAuthorship W3117475035A5031467567 @default.
• W3117475035 hasAuthorship W3117475035A5037435508 @default.
• W3117475035 hasAuthorship W3117475035A5043806671 @default.
• W3117475035 hasAuthorship W3117475035A5051951094 @default.
• W3117475035 hasAuthorship W3117475035A5072207500 @default.
• W3117475035 hasAuthorship W3117475035A5074224747 @default.
• W3117475035 hasAuthorship W3117475035A5076090440 @default.
• W3117475035 hasAuthorship W3117475035A5076364548 @default.
• W3117475035 hasAuthorship W3117475035A5076699033 @default.
• W3117475035 hasAuthorship W3117475035A5088186975 @default.
• W3117475035 hasBestOaLocation W31174750351 @default.

• next